3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 3
1
Status
Recruiting
3
Terminated
2
Completed
2
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Carcinoma, Non-Small-Cell Lung
37
Breast Neoplasms
26
Prostatic Neoplasms
22
Stomach Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
12
Lung Neoplasms
11
Neoplasms
10
Urinary Bladder Neoplasms
8
Head and Neck Neoplasms
8
Triple Negative Breast Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Squamous Cell
6
Non-Muscle Invasive Bladder Neoplasms
5
Nasopharyngeal Carcinoma
5
Carcinoma, Transitional Cell
5
Adenocarcinoma
5
Oropharyngeal Neoplasms
4
Sarcoma
3
Prostatic Neoplasms, Castration-Resistant
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Metastatic Castration-resistant Prostate Cancer
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Vaccinia
2
Recurrence
2
Peritoneal Neoplasms
2
Metastatic Castration-Resistant Prostate Cancer
2
Melanoma
2
Interventions
enzalutamide
5
darolutamide
4
Docetaxel
3
Prednisone
2
olaparib
1
gedatolisib
1
fludrocortisone acetate
1
cabazitaxel
1
abiraterone
1
TVB-2640
1
Radiosurgery
1
Omeprazole
1
Dexamethasone
1
Androgen Antagonists
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Prostatic Neoplasms, Castration-Resistant
×
Docetaxel
×
Clear all
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled
NCT06863272
2026-05-15
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
360 enrolled
NCT07225946
2026-05-11
KLK2-PASenger
Janssen Research & Development, LLC
Phase 3
Recruiting
800 enrolled